Hospital Ramon y Cajal, Department of Cardiology , Madrid 28034 , Spain +34 91 336 8665 ;
Expert Opin Pharmacother. 2013 Nov;14(16):2249-61. doi: 10.1517/14656566.2013.834887. Epub 2013 Sep 26.
Azilsartan medoxomil is the newest angiotensin receptor blocker marketed for the treatment of arterial hypertension. The aim of this article was to review the available evidence about this drug alone or combined with other antihypertensive agents in the treatment of hypertensive population.
For this purpose, a search on MEDLINE and EMBASE databases was performed. The MEDLINE and EMBASE search included both medical subject headings (MeSHs) and keywords including azilsartan or azilsartan medoxomil or angiotensin receptor blockers or renin angiotensin system or chlorthalidone and hypertension. References of the retrieved articles were also screened for additional studies. There were no language restrictions.
Azilsartan medoxomil has a potent and persistent ability to inhibit binding of angiotensin II to AT1 receptors, which may play a role in its superior blood pressure (BP) -lowering efficacy compared with other drugs, including ramipril, candesartan, valsartan or olmesartan, without an increase of side effects. Chlortalidone is a diuretic which significantly differs from other classic thiazides and has largely demonstrated clinical benefits in outcome trials. The fixed-dose combination of azilsartan and chlorthalidone has been shown to be more effective than other potent combinations of angiotensin receptor blockers plus hydrochlorothiazide, with a good tolerability profile.
阿齐沙坦酯是最新上市的血管紧张素受体阻滞剂，用于治疗动脉高血压。本文旨在回顾该药物单独或与其他抗高血压药物联合用于高血压人群的治疗的现有证据。
为此，在 MEDLINE 和 EMBASE 数据库上进行了检索。MEDLINE 和 EMBASE 的检索包括医学主题词（MeSH）和关键词，包括阿齐沙坦、阿齐沙坦酯、血管紧张素受体阻滞剂、肾素-血管紧张素系统、氯噻酮和高血压。还对检索到的文章的参考文献进行了筛选，以寻找其他研究。没有语言限制。
阿齐沙坦酯具有强大而持久的抑制血管紧张素 II 与 AT1 受体结合的能力，这可能使其降压疗效优于其他药物，包括雷米普利、坎地沙坦、缬沙坦或奥美沙坦，而副作用没有增加。氯噻酮是一种利尿剂，与其他经典噻嗪类药物有很大的不同，在结局试验中已证明具有明显的临床获益。阿齐沙坦和氯噻酮的固定剂量组合已被证明比其他血管紧张素受体阻滞剂加氢氯噻嗪的强效组合更有效，且具有良好的耐受性。
